Drug intelligence / Profile preview

haemoblock

Development stage
Phase 4
Lead developer
Russian National Medical Research Center
Modality
Small Molecules
Administration
Topical, Ophthalmic
01

Overview

Haemoblock is a local hemostatic solution registered in the Russian Federation as a medical product. It functions by forming a clot with blood plasma proteins (primarily albumin) to achieve hemostasis within 1-2 minutes. The mechanism involves a two-stage process: first, a polyacrylic matrix complex containing albumin molecules forms, then albumin molecules reduce silver ions, creating polyacrylate anions that bond with positively charged protein molecules. This structure forms multiple microlayers, creating a solid polymethacrylate film on the wound surface. The drug also provides bactericidal and bacteriostatic effects due to the presence of silver nanoparticles, which are effective against most known microorganisms. Importantly, Haemoblock does not affect hemostasis in the general blood flow and does not lead to thrombosis. It can be effective even in cases where the blood clotting system is compromised, such as in hemophilia.

Brand names
Haemoblock

Beyond the preview

Go deeper on haemoblock.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on haemoblock.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call